FDA Approves New THERAKOS CELLEX Photopheresis System For Treatment Of Cutaneous T-cell Lymphoma

News — By on April 14, 2009 at 12:46 pm

EXTON, Pa. — Therakos, Inc., a pioneer in immune cell therapy, today announced the U.S. Food and Drug Administration (FDA) approval of the THERAKOS(TM) CELLEX(TM) Photopheresis System for the palliative (reducing the severity of symptoms) treatment of the skin manifestations (appearance) of cutaneous T-cell lymphoma (CTCL) that are unresponsive to other forms of treatment. The THERAKOS(TM) CELLEX(TM) Photopheresis System is an easy-to-use, integrated system that uses extracorporeal (outside the body) photopheresis (ECP), an innovative cellular therapy, to relieve the symptoms of CTCL. The system also has been cleared recently in Canada and Europe. The new THERAKOS(TM) CELLEX(TM) Photopheresis System features several…

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback